Acurx Pharmaceuticals, Inc. (ACXP)

NCM – Real Time Price. Currency in USD

1.54

+0.07 (5.10%)

Market open: Aug 12, 2026, 3:15 PM EDT

1.51

+0.04 (2.72%)

Previous after-hours: Aug 11, 2026, 7:54 PM EDT

12.08.2026

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

STATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Japan Patent Office and the Mexico Patent Office, respectively, have each granted a new patent which covers Acurx's DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and represents the most recent addition to the Company's expanding series of granted patents in the U.S. and abroad.

10.08.2026

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and Acurx This prior work included high-resolution elucidation of the interaction of ibezapolstat with its molecular target, DNA polymerase IIIC (pol IIIC, also known as PolC), with mechanistic findings that explain its properties of lacking cross-resistance with other antibiotics and not fostering the emergence of vancomycin-resistant Enterococcus strains, a unique differentiation among anti-CDI antibiotics The new research partnership aims to generate the first-ever 3D structure of PolC from methicillin-resistant Staphylococcus aureus (MRSA) in complex with DNA and an Acurx inhibitor to advance discovery of new antibiotics to treat infections caused by this high-priority pathogen This partnership will extend mechanistic research into PolC inhibition to accelerate the development of novel agents for the systemic treatment of infections caused by a range of Gram-positive pathogens resistant to currently available antibiotics STATEN ISLAND, N.Y., Aug. 10, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced a new scientific partnership with Leiden University Medical Center (LUMC) in the Netherlands.

03.08.2026

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Acurx has received FDA guidance in meeting minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Application) based on a single Phase 3 trial and a clinical trial design intended to support indications for both treatment and reduction of recurrence of Clostridioides difficile infection (CDI) FDA stated that it is open to further discussion on the totality of evidence from the clinical development program at a pre-NDA meeting after completion of a single Phase 3 trial and any other clinical trials conducted prior to the pre-NDA meeting, particularly if the clinical efficacy results are robust Additionally, the Agency agreed that a successful clinical outcome from a single IBZ-ASPIRE Phase 3 trial, supported by the open-label IBZ-PATHFINDER Phase 2 trial in multiply-recurrent CDI (rCDI) will allow NDA filing for both the acute treatment and the reduction of recurrence of CDI Trial start-up activities for the IBZ-PATHFINDER ground-breaking clinical trial in patients with rCDI have been initiated with patient enrollment to begin in the next few months Acurx is well positioned to commence its international Ph3 IBZ-ASPIRE trial, subject to funding availability Acurx has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA STATEN ISLAND, N.Y., Aug. 3, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the successful outcome of a Type C Meeting conducted with FDA on July 13, 2026 to discuss ibezapolstat's Phase 3 clinical program and scope of its planned NDA.

Videos

No Data

There is no data to display

Press releases

12.08.2026

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

10.08.2026

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

03.08.2026

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Acurx Pharmaceuticals, Inc. (ACXP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Acurx Pharmaceuticals, Inc. (ACXP)

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Videos

No Data

Press releases

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Videos

No Data

Press releases

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Search stocks

Acurx Pharmaceuticals, Inc. (ACXP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Acurx Pharmaceuticals, Inc. (ACXP)

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Videos

No Data

Press releases

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

Videos

No Data

Press releases

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection